Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma)

American Journal of Clinical Dermatology

Volumn 5, Issue 6, 2004, Pages 395-401

  Lober, Bryan A ^a   Fenske, Neil A ^b  

^a BRANDEIS UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; IMMUNOMODULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACTINIC KERATOSIS; BURNING SENSATION; CLINICAL FEATURE; CRYOSURGERY; HISTOPATHOLOGY; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN INFLAMMATION; SKIN IRRITATION; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CRYOSURGERY; FLUOROURACIL; HUMANS; KERATOSIS; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 12944327339     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405060-00004     Document Type: Review

References (54)

1. Heaphy MR, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000 Jul; 43 (1): 138-50
2. Ackerman AB. Respect at last for solar keratosis. Dermatopathol Practical Concept 1997; 3 (2): 101-3
3. Ng P, Ackerman AB. The major types of squamous-cell carcinoma. Dermatopathol Practical Concept 1999; 5 (3): 250-2
4. Brand D, Ackerman AB. Squamous cell carcinoma, not basal cell carcinoma, is the most common cancer in humans. J Am Acad Dermatol 2000 Mar; 42 (3): 523-6
5. Ackerman AB. Actinic keratosis: malignant or not? [letter]. J Am Acad Dermatol 2001 Sep; 45 (3): 467-9
6. Berhane T, Halliday GM, Cooke B, et al. Inflammation is associated with progression of actinic keratosis to squamous cell carcinoma in humans. Br J Dermatol 2002; 46: 810-5
7. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in hyperkeratotic actinic keratosis. J Am Acad Dermatol 1997 Sep; 37 (3): 392-4
8. Moy RL. Clinical presentation of actinic keratosis and squamous cell carcinoma. In: Actinic keratosis: scientific evaluation and public health implications, proceedings of a conference; 1999 Jan 27; Washington. DC. J Am Acad Dermatol 2000 Jan; 42 (1 Suppl. Pt 2): S8-10
9. Santa Cruz DJ, Hurt MA. Nonmelanocytic cutaneous tumors. In: Sternberg SS, Antonioli DA, Carter D, et al., editors. Diagnostic surgical pathology. Philadelphia (PA): Lippincott Williams & Wilkins, 1999: 49-87
10. Pearse AD, Marks R. Actinic keratosis and the epidermis on which they arise. Br J Dermatol 1977; 96: 45-50
11. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). In: Actinic keratosis: scientific evaluation and public health implications, proceedings of a conference: 1999 Jan 27: Washington, DC. J Am Acad Dermatol 2000 Jan; 42 (1 Suppl. Pt 2): S11-17
12. Jones Jr RE, editor. Questions to the editorial board and other authorities. Am J Dermatopathol 1984; 6: 301-6
13. Ackerman AB, Cavegn BM, Robinson MJ, et al. Ackerman's resolving quandaries in dermatology, pathology, and dermatopathology. Philadelphia (PA): Lippincott, Williams & Wilkins, 1995: 246
14. Hurwitz RM, Monger LE. Solar keratosis: an evolving squamous cell carcinoma: benign or malignant? [letter]. Dermatol Surg 1995; 21: 184
15. Mittelbronn MA, Mullins DL, Ramos-Caro A, et al. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677-81
16. Guenthner ST, Hurwitz RM, Buckel LJ, et al. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation. J Am Acad Dermatol 1999 Sep; 41: 443-8
17. Lober BA, Lober CW, Accola J. Actinic keratosis is squamous cell carcinoma [letter]. J Am Acad Dermatol 2000 Nov; 43: 881-2
18. Carag HR, Prieto VG, Yballe L, et al. Utility of step sections: demonstration of additional pathological findings in biopsy samples initially diagnosed as actinic keratosis. Arch Dermatol 2000 Apr; 136: 471-5
19. Guillen DR, Cockerell CJ. Accurate diagnosis of cutaneous keratinocytic neoplasms. Arch Dermatol 2000 Apr; 136: 535-7
20. Marks R, Rennie G. Malignant transformation of solar keratosis to squamous cell carcinoma. Lancet 1988 Apr; 1 (8589): 795-6
21. Merino MJ, Ackerman AB. Solar keratosis have not been proven to regress! Dermatopathol Practical Concept 2000 Jan-Mar; 6(1): 5-9
22. Frost C, Williams G, Green A. High incidence and regression rates of solar keratosis in a Queensland community. J Invest Dermatol 2000 Aug; 115: 273-7
23. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratosis: the case for conservative management. Br J Dermatol 1986; 115: 649-55
24. Schwartz RA. The actinic keratosis, a perspective and update. Dermatol Surg 1997; 23: 1009-19
25. Dinehart SM, Nelson-Adesokan P, Cockerell C, et al. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer 1997; 79: 920-3
26. Fukamizu H, Inoue K, Matsumoto K, et al. Metastatic squamous-cell carcinomas derived from solar keratosis. J Dermatol Surg Oncol 1985 May; 11: 518-22
27. Takemiya M, Ohtsuka H, Miki Y. The relationship between solar keratosis and squamous cell carcinomas among Japanese. J Dermatol 1990; 17: 342-6
28. Cockerell CJ. Grading of actinic keratosis, reply [letter]. J Am Acad Dermatol 2001 Jun; 44 (6): 1053
29. Callen JP, Bickers DR, Moy RL. Actinic keratosis. J Am Acad Dermatol 1997 Apr; 36 (4): 650-3
30. Weinstock MA, Bingham SF, Cole GW, et al. Reliability of counting actinic keratosis before and after brief consensus discussion. Arch Dermatol 2001 Aug; 137: 1055-8
31. Feldman SR, Fleischer Jr AB, Williford PM, et al. Destructive procedures are the standard of care for treatment of actinic keratosis. J Am Acad Dermatol 1999 Jan; 40: 43-7
32. Gupta AK, Cooper EA, Feldman SR, et al. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. Cutis 2002 Aug; 70 Suppl. S2: 8-13
33. Lubritz RR, Smolewski SA. Cryotherapy cure rates of actinic keratosis. J Am Acad Dermatol 1982; 7: 631-2
34. Dinehart SM. The treatment of actinic keratosis. In: Actinic keratosis: scientific evaluation and public health implications, proceedings of a conference; 1999 Jan 27; Washington, DC. J Am Acad Dermatol 2000 Jan; 42 (1 Suppl. Pt 2): S25-28
35. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratosis: an update and comparison. Dermatol Surg 2000 Aug; 26: 728-32
36. Coleman WP, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratosis. Dermatol Surg 1996; 22: 17-21
37. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis 2002 Aug; 70 (2 Suppl.): S4-7
38. Schwartz RA. Therapeutic perspectives in actinic and other keratoses. Int J Dermatol 1996 Aug; 35 (8): 533-8
39. Gupta AK. The management of actinic keratosis in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002 Aug; 70 Suppl. 2: S30-36
40. Pearlman DL. Weekly pulse dosing: effective and comfortable 5-flurouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991; 25: 665-7
41. Epstein E. Does intermittent "pulse" topical 5-flurouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998; 38: 77-80
42. Carac™ cream 0.5% [PDA-approved package insert]. Berwin (PA): Dermik Laboratories, 2002
43. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002 Aug; 70 Suppl. 2: S22-29
44. Solaraze™ gel [PDA-approved package insert]. Malvern (PA): Bioglan Pharma Inc., 2002
45. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100
46. Wolf JE, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratosis. Int J Dermatol 2001; 40: 709-13
47. Persaud AN, Shamuelova BA, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47: 553-6
48. Persaud A, Lebwohl M. Imiquimod cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47: S236-239
49. Salasche S, Levine N, Morrison L. Cycle therapy of actinic keratosis of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002; 47: 571-7
50. Aldara™ cream 5% [PDA-approved package insert]. Northridge (CA): 3M Pharmaceuticals, 2004
51. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratosis. Arch Dermatol 2002; 138: 1498-502
52. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000; 42: 389-413
53. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratosis with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001; 45: 96-104
54. Levulan® Kerastick® [FDA-approved package insert]. Wayne (NJ): Berlex Laboratories, 2002